International biological standards for coagulation factors and inhibitors

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 3, 2007, Pages 283-289

  Hubbard, Anthony R ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Coagulation factors; Factor VIII; Hemophilia; International Standard

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; FIBRINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; CALIBRATION; DOSE CALCULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; MOISTURE; PRIORITY JOURNAL; REVIEW;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CALIBRATION; FACTOR VIII; HEMOPHILIA A; HUMANS; INTERNATIONAL COOPERATION; LABORATORY TECHNIQUES AND PROCEDURES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 34147212007     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-971815     Document Type: Review

References (36)

1. Burn JH, Finney DJ, Goodwin LG. Biological Standardization. 2nd ed. Oxford, United Kingdom: Oxford University Press; 1950
2. Jeffcoate SL. From insulin to amylin: 75 years of biological standardization in endocrinology. Dev Biol Stand 1999;100:39-47
3. Bangham DR, Biggs R, Brozovic M, Denson KWE, Skegg JL. A biological standard for measurement of blood coagulation factor VIII activity. Bull World Health Organ 1971;45:337-351
4. Barrowcliffe TW, Tydeman MA, Kirkwood TBL, Thomas DP. Standardization of factor VIII. III: establishment of a stable reference plasma for factor VIII-related activities. Thromb Haemost 1983;50:690-696
5. Hubbard AR, Rigsby P, Barrowcliffe TW. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard. Thromb Haemost 2001;85:634-638
6. Hubbard AR. Standardization of Protein S in plasma: calibration of the 1st International Standard. Thromb Haemost 1997;78:1237-1241
7. Gaffney PJ, Wong MY. Collaborative study of a proposed international standard for plasma fibrinogen measurement. Thromb Haemost 1992;68:428-432
8. Whitton CM, Sands D, Hubbard AR, Gaffney PJ. A collaborative study to establish the 2nd International Standard for fibrinogen plasma. Thromb Haemost 2000;4:258-262
9. Seegers WH, Brinkhous KM, Smith HP, Warner ED. The purification of thrombin. J Biol Chem 1938;126:91-95
10. Whitton C, Sands D, Lee T, Chang A, Longstaff C. A reunification of the US ("NIH") and International Unit into a single standard for thrombin. Thromb Haemost 2005;93:261-266
11. Recommendations for the preparation, characterisation and establishment of international and other biological reference standards (revised 2004). WHO Technical Report Series 2007. Geneva, Switzerland: WHO 2007;932:73-131
12. Campbell PJ. International biological standards and reference preparations. 1. Preparation and presentation of materials to serve as standards and reference preparations. J Biol Stand 1974;2:249-258
13. Hubbard AR, Sands D, Chang AC, Mazurier C. Standardization of von Willebrand factor in therapeutic concentrates: calibration of the 1st International Standard for von Willebrand Factor Concentrate (00/514). Thromb Haemost 2002;88:380-386
14. Hubbard AR. von Willebrand factor standards for plasma and concentrate testing. Semin Thromb Hemost 2006;32:522-528
15. Raut S, Bevan S, Hubbard AR, Sands D, Barrowcliffe TW. A collaborative study to establish the 7th International Standard for Factor VIII Concentrate. J Thromb Haemost 2005;3:119-126
16. Hubbard AR, Heath AB. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150). J Thromb Haemost 2004;2:1380-1384
17. Kirkwood TBL. Predicting the stability of biological standards and products. Biometrics 1977;33:736-742
18. Kirkwood TBL, Tydeman MS. Design and analysis of accelerated degradation tests for the stability of biological standards II. A flexible computer program for data analysis. J Biol Stand 1984;12:207-214
19. Kirkwood TBL, Barrowcliffe TW. Discrepancy between 1-stage and 2-stage assay of factor VIII:C. Br J Haematol 1978;40:333-338
20. Barrowcliffe TW, Kirkwood TBL. Standardization of factor VIII. I. Calibration of British standards for factor VIII clotting activity. Br J Haematol 1980;46:471-481
21. Barrowcliffe TW, Tydeman MS, Kirkwood TBL, Thomas DP. Standardization of factor VIII.III. Establishment of a stable reference plasma for factor VIII-related activities. Thromb Haemost 1983;50:690-696
22. Barrowcliffe TW. Standardization and assay. Semin Thromb Hemost 1993;19:73-79
23. Hubbard AR, Parr LJ. Potency estimation of activated factor VII concentrates. Thromb Haemost 1991;65:1160
24. Barrowcliffe TW, Thomas DP. The provision of standards for blood coagulation factors. In: Poller L, ed. Recent Advances in Blood Coagulation. Volume 4. Edinburgh, United Kingdom: Churchill Livingstone 1985:251-266
25. Kirschbaum N, Wood L, Lachenbruch P, et al. Calibration of the Ph. Eur. BRP batch 3/MEGA 2 (US/FDA) Standard for human coagulation factor VIII concentrate for use in the potency assay. Pharmeuropa Spec Issue Biol 2002;1:31-64
26. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002;28:247-255
27. Barrowcliffe TWfor the Factor VIII and Factor IX subcommittee. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost 1993;70:876-877
28. Assay of human coagulation factor VIII (2.7.4). In: European Pharmacopoeia. 5th ed. Strasbourg, France: Council of Europe 2005:194-195
29. Lamb MA, Fricke WA, Rastogi SC. Standardization of factor IX: standards for purified factor IX concentrates. Thromb Haemost 1991;66:548-551
30. Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol 2002;117:247-248
31. Lee C, Barrowcliffe TW, Bray G, et al. Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. Thromb Haemost 1996;76:950-956
32. Hubbard AR, Sands D, Sandberg E, Seitz R, Barrowcliffe TW. A multi-centre collaborative study on the potency estimation of ReFacto. Thromb Haemost 2003;90:1088-1093
33. Hubbard AR, Weller LJ, Bevan SA. Activation profiles of FVIII in concentrates reflect one-stage/chromogenic potency discrepancies. Br J Haematol 2002;117:957-960
34. Khrenov AV, Ananyeva NM, Saenko EL. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X. Blood Coagul Fibrinolysis 2006;17:379-388
35. Assay of human coagulation factor VIII (2.7.4). In: European Pharmacopoeia. 5th ed. Strasbourg, France: Council of Europe Suppl 5.5. 2006:4119-4120
36. Pipe SW, Saint-Remy J-M, Walsh CE. New high-technology products for the treatment of haemophilia. Haemophilia 2004;10(suppl 4):55-63